278 related articles for article (PubMed ID: 26243735)
41. ▼ Apremilast for psoriasis and psoriatic arthritis.
Drug Ther Bull; 2015 Sep; 53(9):105-8. PubMed ID: 26358317
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.
Papp K; Cather JC; Rosoph L; Sofen H; Langley RG; Matheson RT; Hu C; Day RM
Lancet; 2012 Aug; 380(9843):738-46. PubMed ID: 22748702
[TBL] [Abstract][Full Text] [Related]
43. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
44. Apremilast (Otezla). No progress in plaque psoriasis or psoriatic arthritis.
Prescrire Int; 2016 Jun; 25(172):149-51. PubMed ID: 27486641
[TBL] [Abstract][Full Text] [Related]
45. Apremilast: first global approval.
Poole RM; Ballantyne AD
Drugs; 2014 May; 74(7):825-37. PubMed ID: 24797159
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and Safety of Apremilast Monotherapy for Moderate to Severe Psoriasis: Retrospective Study.
Ighani A; Georgakopoulos JR; Zhou LL; Walsh S; Shear N; Yeung J
J Cutan Med Surg; 2018; 22(3):290-296. PubMed ID: 29373924
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B; Bagel J; Lebwohl M; Stein Gold L; Jackson JM; Chen R; Goncalves J; Levi E; Callis Duffin K
J Drugs Dermatol; 2017 Aug; 16(8):801-808. PubMed ID: 28809995
[TBL] [Abstract][Full Text] [Related]
48. A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology.
Moustafa F; Feldman SR
Dermatol Online J; 2014 May; 20(5):22608. PubMed ID: 24852768
[TBL] [Abstract][Full Text] [Related]
49. The phosphodiesterase 4 inhibitor apremilast inhibits Th1 but promotes Th17 responses induced by 6-sulfo LacNAc (slan) dendritic cells.
Oehrl S; Prakash H; Ebling A; Trenkler N; Wölbing P; Kunze A; Döbel T; Schmitz M; Enk A; Schäkel K
J Dermatol Sci; 2017 Aug; 87(2):110-115. PubMed ID: 28499587
[TBL] [Abstract][Full Text] [Related]
50. Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity.
Schafer PH; Parton A; Capone L; Cedzik D; Brady H; Evans JF; Man HW; Muller GW; Stirling DI; Chopra R
Cell Signal; 2014 Sep; 26(9):2016-29. PubMed ID: 24882690
[TBL] [Abstract][Full Text] [Related]
51. Advances in treating psoriasis in the elderly with small molecule inhibitors.
Cline A; Cardwell LA; Feldman SR
Expert Opin Pharmacother; 2017 Dec; 18(18):1965-1973. PubMed ID: 29171774
[TBL] [Abstract][Full Text] [Related]
52. Real-world, single-centre experience of apremilast for the treatment of moderate to severe psoriasis.
Wong TH; Sinclair S; Smith B; Fraser C; Morton CA
Clin Exp Dermatol; 2017 Aug; 42(6):675-676. PubMed ID: 28621002
[No Abstract] [Full Text] [Related]
53. Use of an oral phosphodiesterase-4 inhibitor (apremilast) for the treatment of chronic, severe atopic dermatitis: a case report.
Farahnik B; Beroukhim K; Nakamura M; Abrouk M; Zhu TH; Singh R; Lee K; Bhutani T; Koo J; Liao W
Dermatol Online J; 2017 May; 23(5):. PubMed ID: 28537861
[TBL] [Abstract][Full Text] [Related]
54. Use of Apremilast in Combination With Other Therapies for Treatment of Chronic Plaque Psoriasis: A Retrospective Study.
AbuHilal M; Walsh S; Shear N
J Cutan Med Surg; 2016 Jul; 20(4):313-6. PubMed ID: 26848145
[TBL] [Abstract][Full Text] [Related]
55. Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.
Bissonnette R; Haydey R; Rosoph LA; Lynde CW; Bukhalo M; Fowler JF; Delorme I; Gagné-Henley A; Gooderham M; Poulin Y; Barber K; Jenkin P; Landells I; Pariser DM
J Eur Acad Dermatol Venereol; 2018 Mar; 32(3):403-410. PubMed ID: 29055155
[TBL] [Abstract][Full Text] [Related]
56. Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis.
Gisondi P; Girolomoni G
Drug Des Devel Ther; 2016; 10():1763-70. PubMed ID: 27307707
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results from ESTEEM 1 and ESTEEM 2.
Duffin KC; Papp KA; Bagel J; Levi E; Chen R; Gottlieb AB
J Drugs Dermatol; 2017 Feb; 16(2):147-153. PubMed ID: 28300857
[TBL] [Abstract][Full Text] [Related]
58. Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.
Armstrong AW; Betts KA; Sundaram M; Thomason D; Signorovitch JE
J Am Acad Dermatol; 2016 Oct; 75(4):740-746. PubMed ID: 27476973
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in ankylosing spondylitis.
Pathan E; Abraham S; Van Rossen E; Withrington R; Keat A; Charles PJ; Paterson E; Chowdhury M; McClinton C; Taylor PC
Ann Rheum Dis; 2013 Sep; 72(9):1475-80. PubMed ID: 22984171
[TBL] [Abstract][Full Text] [Related]
60. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis.
Volf EM; Au SC; Dumont N; Scheinman P; Gottlieb AB
J Drugs Dermatol; 2012 Mar; 11(3):341-6. PubMed ID: 22395585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
